GTHX
GTHX Real Time Price USDRecent trades of GTHX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by GTHX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
GTHX Revenue by Segment or Geography
New patents grants
-
Patent Title: Morphic forms of trilaciclib and methods of manufacture thereof Dec. 17, 2024
-
Patent Title: Transient protection of normal cells during chemotherapy Aug. 08, 2023
-
Patent Title: Synthesis of 1,4-diazaspiro[5.5]undecan-3-one Jul. 25, 2023
-
Patent Title: Hspc-sparing treatments for rb-positive abnormal cellular proliferation May. 23, 2023
-
Patent Title: Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors May. 09, 2023
-
Patent Title: Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines Apr. 18, 2023
-
Patent Title: Preservation of immune response during chemotherapy regimens Dec. 20, 2022
-
Patent Title: Anti-neoplastic combinations and dosing regimens using cdk4/6 inhibitor compounds to treat rb-positive tumors Sep. 20, 2022
-
Patent Title: Treatment of egfr-driven cancer with fewer side effects Jul. 26, 2022
-
Patent Title: Combination therapy for treatment of cancer Jun. 21, 2022
-
Patent Title: G1t38 superior dosage regimes Jun. 14, 2022
-
Patent Title: Transient protection of normal cells during chemotherapy Jun. 22, 2021
-
Patent Title: Morphic forms of trilaciclib and methods of manufacture thereof Apr. 27, 2021
-
Patent Title: Benzothiophene estrogen receptor modulators Apr. 20, 2021
-
Patent Title: Transient protection of normal cells during chemotherapy Apr. 06, 2021
-
Patent Title: Hspc-sparing treatments for rb-positive abnormal cellular proliferation Feb. 23, 2021
-
Patent Title: Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines Dec. 15, 2020
-
Patent Title: Highly active anti-neoplastic and anti-proliferative agents Jul. 14, 2020
-
Patent Title: Cdk inhibitors Jun. 30, 2020
-
Patent Title: Antiproliferative pyrimidine-based compounds May. 19, 2020
-
Patent Title: Hspc-sparing treatments for rb-positive abnormal cellular proliferation Oct. 08, 2019
-
Patent Title: Treatment of rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors Sep. 17, 2019
-
Patent Title: Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation Aug. 13, 2019
-
Patent Title: Benzothiophene estrogen receptor modulators Feb. 19, 2019
-
Patent Title: Cdk inhibitors Jan. 29, 2019
-
Patent Title: Cdk inhibitors Jan. 29, 2019
-
Patent Title: Cdk inhibitors Jan. 29, 2019
-
Patent Title: Transient protection of normal cells during chemotherapy Oct. 02, 2018
-
Patent Title: Hspc-sparing treatments for rb-positive abnormal cellular proliferation Sep. 18, 2018
-
Patent Title: Lactam kinase inhibitors Jan. 02, 2018
-
Patent Title: Lactam kinase inhibitors Aug. 29, 2017
-
Patent Title: Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation Aug. 01, 2017
-
Patent Title: Cdk inhibitors Nov. 22, 2016
-
Patent Title: Transient protection of normal cells during chemotherapy Nov. 08, 2016
-
Patent Title: Cdk inhibitors Nov. 01, 2016
-
Patent Title: Transient protection of normal cells during chemotherapy Oct. 11, 2016
-
Patent Title: Lactam kinase inhibitors Feb. 16, 2016
-
Patent Title: Cdk inhibitors Aug. 11, 2015
-
Patent Title: Cdk inhibitors Sep. 09, 2014
-
Patent Title: Cdk inhibitors Sep. 02, 2014
-
Patent Title: Cdk inhibitors Apr. 08, 2014
-
Patent Title: Cdk inhibitors Dec. 03, 2013
-
Patent Title: Cdk inhibitors Dec. 03, 2013
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to GTHX
Recent picks made for GTHX stock on CNBC
ETFs with the largest estimated holdings in GTHX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $GTHX stock a Buy, Sell, or Hold?
- What is the price target for $GTHX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $GTHX stock?
- Who owns the most shares of $GTHX stock?
- What funds own $GTHX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view GTHX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.